EUPRAXIA PHARMACEUTICALS INC.
EPRX · XNASCIK 1581178fmd_1WPZ289ZX4JR32KR2TT327TV4VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Dec 31, 2025, 4 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Net income
- (39)
Daily close · EPRXIEX trades only
Nov 09, 2026 to Nov 11, 2026 · 3 sessions8.04 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
EUPRAXIA PHARMACEUTICALS INC. (EPRX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 40-F 2026-03-13 · proof | |
| Net income | -$38.6 million | -$25.5 million | 40-F 2026-03-13 · proof | |
| Cash from operating activities | -$28.6 million | -$30 million | 40-F 2026-03-13 · proof | |
| Total assets | $86.2 million | $34.9 million | +146.5% | 40-F 2026-03-13 · proof |
| Total liabilities | $5.7 million | $3.1 million | +83.8% | 40-F 2026-03-13 · proof |
| Cash and cash equivalents | $80.6 million | $33.1 million | +143.4% | 40-F 2026-03-13 · proof |
- What was EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s revenue in fiscal 2025?
- EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported revenue of $0 for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
- What was EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s net income in fiscal 2025?
- EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported net income of -$38.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$25.5 million the year before. Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
- What was EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s cash from operating activities in fiscal 2025?
- EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported cash from operating activities of -$28.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$30 million the year before. Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
- What are EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s total assets?
- As of Dec 31, 2025, EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported total assets of $86.2 million, against $34.9 million a year earlier (+146.5%). Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
- What are EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s total liabilities?
- As of Dec 31, 2025, EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported total liabilities of $5.7 million, against $3.1 million a year earlier (+83.8%). Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
- What are EUPRAXIA PHARMACEUTICALS INC. (EPRX)'s cash and cash equivalents?
- As of Dec 31, 2025, EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported cash and cash equivalents of $80.6 million, against $33.1 million a year earlier (+143.4%). Source: the 40-F filed with the SEC on Mar 13, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:EPRX&period_type=annual&limit=5"Information only, not investment advice.